(AOF) – Sanofi today announced the departure of Dr. John Reed, Global Head of Research and Development since May 2018, who “laid the foundations for the transformation of the company’s R&D”. The group has started the internal and external search process for the succession of Dr John Reed, and Dr Dietmar Berger, Head of Global Development since May 2019 and Chief Medical Officer since February 2020, former of Genentech, Bayer and Amgen, has accepted to act as interim director of the R&D organization.
Sanofi says John Reed has “helped reshape the group’s discovery and therapy development processes” by focusing efforts on “first and best-in-class drugs that have the potential to transform the practice of medicine.” and improve the lives of people with serious illnesses.”
Dr. Reed has also “managed the integration and development of new technology platforms and partnerships”, and “helped increase the productivity of the R&D organization”.
Sanofi announces that in 2023 it will launch two first-in-class or best-in-class drugs that will meet significant needs in the areas of hemophilia and respiratory syncytial virus, which causes bronchiolitis. The company anticipates over the next 15 months 27 scientific publications and two publications of the results of pivotal trials in multiple sclerosis and chronic obstructive pulmonary disease.
© AOF
Legal disclaimer
The AOF information reproduced on Capital.fr is taken from the AOF information service. This information is protected by intellectual property rights held by OPTION FINANCE SAS, publisher of the AOF real-time stock market information service, and its contributors. Consequently, any reproduction, copy, duplication, modification, transfer, redistribution, translation, commercial exploitation or not, creation of a hypertext link or reuse in any way whatsoever of this information is subject to the prior written consent of OPTION. FINANCE SAS and its contributors. AOF can be reached at the following address [email protected] OPTION FINANCE SAS collects its data from the sources it considers the safest. However, subject to its gross negligence, OPTION FINANCES SAS and its contributors do not in any way guarantee the absence of error and defects, even hidden ones, nor the exhaustive nature or the lack of conformity for any use whatsoever of this data and of OPTION FINANCE SAS or one of its contributors, and cannot be held responsible for any delays or interruptions that may affect access to them. The user of the OPTION FINANCE SAS service will use the AOF data at his own risk and must hold OPTION FINANCE SAS and its contributors harmless from any claim resulting from this use.
Receive our latest news
Every morning, the information to remember on the financial markets.
